FirstImpact Live – Unlocking the potential of cancer therapies in early-stage patients (June 23)

Exclusive to FirstWord Pharma PLUS subscribers

The recent ASCO meeting saw more promising data presented for I/O (immuno-oncology) and targeted cancer therapies in patients with early-stage disease – see ASCO 2021: Momentum grows for earlier-stage cancer treatment

Join FirstWord editors Simon King and Michael Flanagan to discuss feedback from oncologist surveys and recent key opinion leader (KOL) interviews assessing the potential impact of two clinical studies which were part of the ASCO plenary session: the OlympiA trial evaluating AstraZeneca and Merck & Co.’s Lynparza as adjuvant treatment for BRCA mutation breast cancer and Keynote-564 evaluating Merck’s Keytruda as adjuvant treatment for renal cell carcinoma (RCC).

Register here

To read more Physician Views articles, click here.

Reference Articles